Compare Stitch Fix Inc (SFIX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Twist Bioscience Corp — how do they compare? Stitch Fix Inc trades at $2.74 (market cap $365.41M), while Twist Bioscience Corp trades at $158 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 28.2× Stitch Fix Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Stitch Fix Inc for 31 Days and Twist Bioscience Corp for 27 Days on average.
| SFIX | TWST | |
|---|---|---|
Market Cap | $365.41M | $10.32B |
Volume | 3,317,935 | 5,894,998 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.64 | $205.00 |
52-Week Low | $2.16 | $25.45 |
Typical Hold Time | 31 Days | 27 Days |
Enterprise Value | $261.21M | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.73, up 2.25% today, showing recent earnings beats but facing bearish technical signals. The company reported improved financials with narrowing losses (-$28.74M net income in 2025 vs -$129M in 2024) and stable $1.27B revenue, though negative cash flow and weak FY27 guidance weigh on sentiment. Analyst consensus is mixed with 24% Buy ratings but a $3.40 price target suggesting 25% upside.
Outlook remains challenging with ongoing profitability concerns and legal investigations creating headwinds. The stock offers speculative appeal given low P/S ratio and AI-driven growth initiatives, but execution risks and competitive pressures require careful monitoring. Near-term performance hinges on reversing active client declines and achieving sustainable EBITDA positivity.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
